# A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis

> **NCT01026519** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** REGN88
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01026519
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-03
- **Final completion:** 2009-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01026519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01026519, "A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01026519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*